HOME >> MEDICINE >> NEWS
Novartis MS drug shows promising results

RI (at the 12th month) was reduced by more than 80% compared to the sixth month. More than 80% of patients who received FTY720 for up to 12 months were free from lesions showing active inflammation on MRI at the 12th month irrespective of their FTY720 treatment dose (1.25 mg or 5 mg).

FTY720 appeared to be well tolerated, with 91% of patients who entered the extension phase completing the 12th month on the study drug. There were no unexpected safety findings during the extension as compared to the six-month placebo-controlled phase. The most frequently reported adverse events in patients treated up to twelve months were non-serious infections (colds, influenza), headache, diarrhoea and nausea.

About FTY720
Oral FTY720 has a novel mode of action different from all available therapies. It reversibly sequesters lymphocytes away from blood and susceptible target organs such as the central nervous system (CNS), thereby reducing neuroinflammation in MS. FTY720 has been developed by Novartis Pharma and licensed from Mitsubishi Pharma Corporation.

About Multiple Sclerosis
MS is the most common inflammatory and neurodegenerative disorder of the central nervous system, including the brain, spinal cord and optic nerves. MS typically presents itself in relapsing forms. The relapsing-remitting (RRMS) course is the most common form of the disease. Patients suffer acute self-limiting attacks (relapses) of neurological dysfunction followed by complete or incomplete remission in function. Over time, transmission of electrical nerve impulses is disrupted, nerve cells are destroyed, and patients experience symptoms ranging from fatigue, tingling, numbness and blurred vision to poor muscle control with partial or complete paralysis, speech or mental impairment. About 50% of patients advance to the secondary progressive (SPMS) course within 10 years.


'"/>

Contact: Eva Reynolds
eva@reynoldsmackenzie.com
44-207-031-4361
Reynolds-MacKenzie
1-Oct-2005


Page: 1 2 3

Related medicine news :

1. BIDMC investigator receives Novartis Award in Diabetes
2. American Urological Association honors Novartis Pharmaceuticals with annual health science award
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. Most seniors now have drug coverage, U-M study shows
5. Wireless technology shows promise in diagnosing pediatric intestinal disease
6. Study shows radiofrequency ablation highly effective in treating kidney tumors
7. Method shows promise for early detection of pancreatic cancer
8. Organic farming can feed the world, U-M study shows
9. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
10. Borderline personality disorder shows improvements with intensive psychotherapy
11. New drug shows promise in treatment of advanced thyroid cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2019)... ... August 21, 2019 , ... CBD has officially ... video accompanying this announcement is available at: https://youtu.be/D-65LmBhJhU , CBD, the ... can be found on the internet, wellness catalogs, small specialty shops, and now, ...
(Date:8/21/2019)... ... August 21, 2019 , ... Photoprotective Technologies (PPT) has ... This water-based ingredient is currently used in skincare products such as creams or makeup ... product addresses the growing need to protect the skin from blue light as well ...
(Date:8/19/2019)... , ... August 19, 2019 , ... ... selling Eminence Organic Skin Care products , the authorized retailer will change ... DeVries, was a practicing esthetician in Florida providing Eminence Organic Skin Care facials ...
(Date:8/19/2019)... ... August 19, 2019 , ... Cosmetic Town, an online ... the best hair restoration doctors in New York currently providing a lifetime of natural ... starting to see some thinning hair. Cosmetic Town makes the process of finding information ...
(Date:8/16/2019)... ... August 16, 2019 , ... Cannabinoid Biosciences (“CBDZ”), ... cannabidiol (CBD) products across the CBD market in the United States in particular ... to raise $50 million on September 9, 2019. , Established on May 6, ...
Breaking Medicine News(10 mins):
(Date:8/21/2019)... ... August 21, 2019 , ... ... ranked by Modern Healthcare’s Construction and Design Survey, has added Operational Readiness ... provides a comprehensive overlay to clients’ capital projects, working with the clinical ...
(Date:8/21/2019)... ... 2019 , ... Dr. Leonard Bley at NY LASIK is proud ... (Small Incision Lenticule Extraction) located in their state-of-the-art Manhattan surgery center. NY LASIK is ... area. SMILE is a one-step, one laser procedure that is more minimally invasive than ...
(Date:8/21/2019)... Colo. (PRWEB) , ... August 21, 2019 , ... ... improving patron experience by lowering pool chemical use with Clear Comfort’s Advanced Oxidation ... is able to save significant chemical expense dollars, simplify its water care protocol ...
Breaking Medicine Technology:
Cached News: